- Home
- Publications
- Publication Search
- Publication Details
Title
Relapsed refractory multiple myeloma: a comprehensive overview
Authors
Keywords
-
Journal
LEUKEMIA
Volume 33, Issue 10, Pages 2343-2357
Publisher
Springer Science and Business Media LLC
Online
2019-08-28
DOI
10.1038/s41375-019-0561-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study
- (2019) Jonathan L. Kaufman et al. Blood Cancer Journal
- BiTE Therapy Active in Multiple Myeloma
- (2019) Cancer Discovery
- The impact of cytogenetics on duration of response and overall survival in patients with relapsed multiple myeloma (long‐term follow‐up results from BSBMT / UKMF Myeloma X Relapse [Intensive]): a randomised, open‐label, phase 3 trial
- (2019) Gordon Cook et al. BRITISH JOURNAL OF HAEMATOLOGY
- Pomalidomide, cyclophosphamide, and dexamethasone for relapsed/refractory multiple myeloma patients in a real-life setting: a single-center retrospective study
- (2019) Sabrina Trudel et al. ANNALS OF HEMATOLOGY
- Daratumumab Plus Carfilzomib and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
- (2019) Ajai Chari et al. BLOOD
- Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
- (2019) Noopur Raje et al. NEW ENGLAND JOURNAL OF MEDICINE
- Addition of cyclophosphamide on insufficient response to pomalidomide and dexamethasone: results of the phase II PERSPECTIVE Multiple Myeloma trial
- (2019) Katja C. Weisel et al. Blood Cancer Journal
- Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies
- (2019) Maria-Victoria Mateos et al. HAEMATOLOGICA
- Prolonged Duration of Therapy Is Associated With Improved Survival in Patients Treated for Relapsed/Refractory Multiple Myeloma in Routine Clinical Care in the United States
- (2018) Parameswaran Hari et al. Clinical Lymphoma Myeloma & Leukemia
- Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
- (2018) David S. Siegel et al. JOURNAL OF CLINICAL ONCOLOGY
- Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study
- (2018) Philippe Moreau et al. LANCET ONCOLOGY
- Promising activity of nelfinavir-bortezomib-dexamethasone (NeVd) in proteasome inhibitor-refractory multiple myeloma
- (2018) Christoph Driessen et al. BLOOD
- Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX
- (2018) Meletios A. Dimopoulos et al. HAEMATOLOGICA
- Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR
- (2018) Andrew Spencer et al. HAEMATOLOGICA
- Pomalidomide (POM), bortezomib, and low‐dose dexamethasone (PVd) vs bortezomib and low-dose dexamethasone (Vd) in lenalidomide (LEN)-exposed patients (pts) with relapsed or refractory multiple myeloma (RRMM): Phase 3 OPTIMISMM trial.
- (2018) Paul G. Richardson et al. JOURNAL OF CLINICAL ONCOLOGY
- bb2121 anti-BCMA CAR T-cell therapy in patients with relapsed/refractory multiple myeloma: Updated results from a multicenter phase I study.
- (2018) Noopur S. Raje et al. JOURNAL OF CLINICAL ONCOLOGY
- Revised International Staging System Is Predictive and Prognostic for Early Relapse (
- (2018) Sathish Gopalakrishnan et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma
- (2018) Laurent Garderet et al. BLOOD
- Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma
- (2018) Nizar J. Bahlis et al. BLOOD
- A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma
- (2018) Wan-Hong Zhao et al. Journal of Hematology & Oncology
- Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma
- (2018) Meletios A. Dimopoulos et al. NEW ENGLAND JOURNAL OF MEDICINE
- DARATUMUMAB, BORTEZOMIB AND DEXAMETHASONE (DVD) VS BORTEZOMIB AND DEXAMETHASONE (VD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): EFFICACY AND SAFETY UPDATE (CASTOR)
- (2017) S. Lentzsch et al. HEMATOLOGICAL ONCOLOGY
- Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial
- (2017) Meletios A Dimopoulos et al. LANCET ONCOLOGY
- Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but outcomes have improved over time
- (2017) S K Kumar et al. LEUKEMIA
- CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma
- (2016) James R. Berenson et al. BLOOD
- Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma
- (2016) M. A. Dimopoulos et al. BLOOD
- Next-generation multiple myeloma treatment: a pharmacoeconomic perspective
- (2016) S. V. Rajkumar et al. BLOOD
- Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma
- (2016) J. Krejcik et al. BLOOD
- A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo
- (2016) S Hipp et al. LEUKEMIA
- Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
- (2016) Philippe Moreau et al. NEW ENGLAND JOURNAL OF MEDICINE
- Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
- (2016) Meletios A. Dimopoulos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
- (2016) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Multiple myeloma epidemiology and survival: A unique malignancy
- (2016) Dickran Kazandjian SEMINARS IN ONCOLOGY
- The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial
- (2016) Gordon Cook et al. Lancet Haematology
- Salvage therapy with bortezomib and dexamethasone in elderly patients with relapsed/refractory multiple myeloma
- (2015) Roberto Castelli et al. ANTI-CANCER DRUGS
- Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma
- (2015) Marije B Overdijk et al. mAbs
- Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma
- (2015) Alfred L. Garfall et al. NEW ENGLAND JOURNAL OF MEDICINE
- Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
- (2015) Sagar Lonial et al. NEW ENGLAND JOURNAL OF MEDICINE
- Role of Histone Deacetylase Inhibitors in Relapsed Refractory Multiple Myeloma: A Focus on Vorinostat and Panobinostat
- (2015) Salma Afifi et al. PHARMACOTHERAPY
- Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma
- (2014) Y.-T. Tai et al. BLOOD
- Curing myeloma at last: defining criteria and providing the evidence
- (2014) B. Barlogie et al. BLOOD
- Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial
- (2014) Jesús F San-Miguel et al. LANCET ONCOLOGY
- PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma
- (2013) P. G. Richardson et al. BLOOD
- Pattern of relapse and progression after autologous SCT as upfront treatment for multiple myeloma
- (2013) C Fernández de Larrea et al. BONE MARROW TRANSPLANTATION
- A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma
- (2013) Maria T. Petrucci et al. BRITISH JOURNAL OF HAEMATOLOGY
- Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial
- (2013) C. Scheid et al. HAEMATOLOGICA
- Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial
- (2013) Jesus San Miguel et al. LANCET ONCOLOGY
- The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
- (2013) G. Lu et al. SCIENCE
- Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma
- (2012) Jeffrey L. Wolf et al. LEUKEMIA & LYMPHOMA
- New Proteasome Inhibitors in Myeloma
- (2012) Panisinee Lawasut et al. Current Hematologic Malignancy Reports
- Long-term prognostic significance of response in multiple myeloma after stem cell transplantation
- (2011) J. Martinez-Lopez et al. BLOOD
- Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1
- (2011) S. V. Rajkumar et al. BLOOD
- Treatment strategies in relapsed and refractory multiple myeloma: a focus on drug sequencing and ‘retreatment’ approaches in the era of novel agents
- (2011) B Mohty et al. LEUKEMIA
- Mechanism of Action of Proteasome Inhibitors and Deacetylase Inhibitors and the Biological Basis of Synergy in Multiple Myeloma
- (2011) T. Hideshima et al. MOLECULAR CANCER THERAPEUTICS
- Bortezomib Plus Melphalan and Prednisone Compared With Melphalan and Prednisone in Previously Untreated Multiple Myeloma: Updated Follow-Up and Impact of Subsequent Therapy in the Phase III VISTA Trial
- (2010) Maria-Victoria Mateos et al. JOURNAL OF CLINICAL ONCOLOGY
- Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors
- (2010) M. de Weers et al. JOURNAL OF IMMUNOLOGY
- Development of the pan-DAC inhibitor panobinostat (LBH589): Successes and challenges
- (2009) Peter Atadja CANCER LETTERS
- Bispecific T-Cell Engaging Antibodies for Cancer Therapy
- (2009) P. A. Baeuerle et al. CANCER RESEARCH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started